Consequently, they consider NHE1 as a potential therapeutic target and suggest to inhibit NHE1, e.g., by H2-receptor blockers, in order to treat GERD (Siddique and Khan, 2003). Here, SLC9A1 is linked to gastroesophageal reflux disease.